{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:40:00Z","timestamp":1783629600406,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:00:00Z","timestamp":1522972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.htct.2018.02.004","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T03:03:29Z","timestamp":1524020609000},"page":"343-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals"],"prefix":"10.1016","volume":"40","author":[{"given":"Guilherme Rossi","family":"Assis-Mendon\u00e7a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Henrique","family":"Crepaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia Torresan","family":"Delamain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Helena","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe D\u2019Almeida","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladmir Cl\u00e1udio Cordeiro de","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1rmino Antonio de","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Augusto","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Vassallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.htct.2018.02.004_bib0165","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2-4-235","article-title":"Classification of non-Hodgkin's lymphoma: a proposal","volume":"2","author":"Hern\u00e1ndez","year":"1997","journal-title":"Oncologist"},{"key":"10.1016\/j.htct.2018.02.004_bib0170","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","year":"2017"},{"issue":"6","key":"10.1016\/j.htct.2018.02.004_bib0175","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23176","article-title":"Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management","volume":"87","author":"Vose","year":"2012","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.htct.2018.02.004_bib0180","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.htct.2018.02.004_bib0185","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00277-002-0581-1","article-title":"Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab","volume":"82","author":"Herold","year":"2003","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.htct.2018.02.004_bib0190","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2012.41.7527","article-title":"Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm?","volume":"31","author":"Cabanillas","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9759","key":"10.1016\/j.htct.2018.02.004_bib0195","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.htct.2018.02.004_bib0200","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.htct.2018.02.004_bib0205","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.htct.2018.02.004_bib0210","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.htct.2018.02.004_bib0215","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","article-title":"Gene-expression and immunohistochemical study of specific t-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma","volume":"25","author":"Glas","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.htct.2018.02.004_bib0220","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-14-3253","article-title":"The prognostic impact of CD163-positive macrophages in follicular Lymphoma: a study from the BC Cancer Agency and the Lymphoma Study Association","volume":"21","author":"Kridel","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.htct.2018.02.004_bib0225","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1182\/blood-2012-04-424630","article-title":"Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells","volume":"120","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.htct.2018.02.004_bib0230","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/hon.2106","article-title":"Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages","volume":"32","author":"Koh","year":"2014","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1016\/j.htct.2018.02.004_bib0235","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3324\/haematol.2012.073080","article-title":"The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation","volume":"98","author":"Maffei","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.htct.2018.02.004_bib0240","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.seminhematol.2014.05.002","article-title":"Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d","volume":"51","author":"Dal Bo","year":"2014","journal-title":"Semin Hematol"},{"issue":"31","key":"10.1016\/j.htct.2018.02.004_bib0245","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.htct.2018.02.004_bib0250","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.htct.2018.02.004_bib0255","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.htct.2018.02.004_bib0260","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.htct.2018.02.004_bib0265","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.htct.2018.02.004_bib0270","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an International Workshop to standardized response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.htct.2018.02.004_bib0275","doi-asserted-by":"crossref","first-page":"e0177204","DOI":"10.1371\/journal.pone.0177204","article-title":"GOTEL (Spanish Lymphoma Oncology Group), impact of treatment in long-term survival patients with follicular lymphoma: a Spanish Lymphoma Oncology Group registry","volume":"12","author":"Provencio","year":"2017","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.htct.2018.02.004_bib0280","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.clml.2015.07.631","article-title":"Outcomes of treatment in slovene follicular lymphoma patients","volume":"15","author":"Ju\u017eni\u010d \u0160etina","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.htct.2018.02.004_bib0285","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"European MCL network, histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.htct.2018.02.004_bib0290","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/his.12207","article-title":"Immunohistochemical evaluation of MYC expression in mantle cell lymphoma","volume":"63","author":"Oberley","year":"2013","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.htct.2018.02.004_bib0295","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.htct.2018.02.004_bib0300","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","article-title":"Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times","volume":"156","author":"Wahlin","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.htct.2018.02.004_bib0305","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5581\/1516-8484.20120015","article-title":"Follicular lymphoma \u2013 treatment and prognostic factors","volume":"34","author":"Luminari","year":"2012","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"12","key":"10.1016\/j.htct.2018.02.004_bib0310","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3324\/haematol.2009.021766","article-title":"Vascularization predicts overall survival and risk of transformation in follicular lymphoma","volume":"95","author":"Farinha","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.htct.2018.02.004_bib0315","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":"Incidence, risk factors and outcome of histological transformation in follicular lymphoma","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.htct.2018.02.004_bib0320","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137918300609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137918300609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T03:18:38Z","timestamp":1720235918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137918300609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S2531137918300609"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2018.02.004","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2018.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}